COMMUNIQUÉS West-GlobeNewswire

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
13/08/2026
Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% [...]
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to [...]
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
13/08/2026
A patient-centered initiative focused on education, connection, and support TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage [...]
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
13/08/2026
Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding PONTE VEDRA, Fla., Aug. 13, 2026 ( [...]
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
13/08/2026
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
13/08/2026
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
13/08/2026
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates [...]
Tiny Health Named No. 208 on the 2026 Inc. 5000 List of America’s Fastest-Growing Private Companies
13/08/2026
Microbiome Innovator Recognized for 1,624% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tiny Health , the [...]
WellBridge Surgical Named No. 988 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America’s Fastest-Growing Private Companies
13/08/2026
Following Significant Revenue Growth Over the Past Three Years, Earning a Place Among the Nation’s Most Successful Independent Businesses INDIANAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- WellBridge Surgical today [...]
Rapport Semestriel 2026 Valneva
13/08/2026
Rapport Semestriel 2026 Valneva Pièce jointe Financial Report HY1 2026 (FR) (2026-08-12) (002)
Valneva Half-Year 2026 Financial Report
13/08/2026
Valneva Half-Year 2026 Financial Report Attachment Financial Report HY1 2026 (EN) (2026-08-12) (002)
Aligned Marketplace Raises $20 Million, Achieves Measurable Outcomes with Large Employers
13/08/2026
A Third-Party Validated 12 Percent Reduction in Total Cost of Care Delivered in Year One For A Large Fortune 500 Company Proves the Independent Primary Care Model Works at Scale NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE [...]
City of Mobile proclaims Project Persevere Day as The Helios Alliance Reports 117,444 Services Delivered in First Year of Opioid Abatement Program
13/08/2026
Sixteen organizations delivered 117,444 services at $143.81 per person — among the most efficient deployments of opioid settlement funds nationally — as a public awareness campaign prepares to launch Mobile, ALABAMA, [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2026
13/08/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - July 2026
13/08/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results
13/08/2026
Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the [...]
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
13/08/2026
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program Presented Data from CLOVER WaM Trial of [...]
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
13/08/2026
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, [...]
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
13/08/2026
Q2 2026 Adjusted EBITDA 1 of $0.9M, the Company’s strongest quarterly performance since 2019 2 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 versus Q2 2025 [...]

Pages